SI-BONE (NASDAQ:SIBN) Issues Quarterly Earnings Results, Beats Expectations By $0.05 EPS

SI-BONE (NASDAQ:SIBN) issued its quarterly earnings results on Monday. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.05, Zacks reports. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. SI-BONE updated its FY 2025 guidance to EPS.

SI-BONE Price Performance

SIBN traded down $0.37 on Monday, hitting $17.47. 480,003 shares of the company’s stock were exchanged, compared to its average volume of 337,823. The firm has a 50-day moving average price of $15.65 and a 200-day moving average price of $14.66. The company has a current ratio of 8.25, a quick ratio of 7.22 and a debt-to-equity ratio of 0.22. The stock has a market cap of $732.66 million, a price-to-earnings ratio of -18.99 and a beta of 1.17. SI-BONE has a fifty-two week low of $11.70 and a fifty-two week high of $20.60.

Insider Activity

In other news, CFO Anshul Maheshwari sold 5,304 shares of the business’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $13.91, for a total transaction of $73,778.64. Following the transaction, the chief financial officer now owns 189,319 shares of the company’s stock, valued at approximately $2,633,427.29. The trade was a 2.73 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Anthony J. Recupero sold 3,670 shares of the business’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $13.90, for a total transaction of $51,013.00. Following the transaction, the insider now directly owns 222,814 shares in the company, valued at approximately $3,097,114.60. The trade was a 1.62 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 9,311 shares of company stock valued at $130,356. 3.90% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on SIBN. Truist Financial lifted their target price on shares of SI-BONE from $16.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Needham & Company LLC reaffirmed a “buy” rating and set a $19.00 target price on shares of SI-BONE in a research note on Monday, January 13th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $23.00.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.